News
Health Through Evidence had the pleasure of participating in and supporting the 10th HTA Conference 2025
đ Last week, Health Through Evidence had the pleasure of participating in and supporting the 10th HTA Conference 2025, themed âHTA in Transition: Delivering Value Through Inclusive Health Policiesâ, organized by Health Daily and BOUSSIAS, held on September 30th in...
Understanding Inflammatory Bowel Disease (IBD) Through the Patientsâ Voice
Health Through Evidence (HTE) for World Inflammatory Bowel Disease Day 2025 by Marina Psarra, MSc, Biologist-Medical writer. Inflammatory Bowel Disease (IBD), encompassing Crohnâs disease and ulcerative colitis, continues to impose a significant burden on individuals...
Greek Study Highlights High Disease Burden in Inflammatory Bowel Disease Patients Despite Biologic Therapy
We are pleased to announce the results of our latest #study, conducted in collaboration with HELLESCC | Hellenic Society of Crohn Disease And Ulcerative Colitis Patients. Our findings highlight a critical insight: a significant proportion of patients with...
Excited to Have Been Part of European Crohnâs and Colitis Organisation (ECCO) 2025 in Berlin, Germany.
Delighted to have been part of European Crohnâs and Colitis Organization in Berlin, Germany! We are happy to share that our research study, titled "Patient-reported outcomes in a Greek cross-sectional survey of inflammatory bowel disease patients treated with biologic...
Publication Alert: Cost-Effectiveness Analysis of Upadacitinib in Patients With Moderately to Severely Active Ulcerative Colitis in Greece
Happy to share our most recent, open-access publication âCost-Effectiveness Analysis of Upadacitinib in Patients With Moderately to Severely Active Ulcerative Colitis in Greece â in Value in Health Regional Issues. Ulcerative Colitis (UC) is a chronic inflammatory...